7月15日，生物科技企业22nd Century Group Inc.（股票代码：XXII）成功召开2025年度股东大会。会议通过多项关键决议： • 股东投票选举Lawrence Firestone与David Keys担任公司II类董事 • 以咨询性决议形式批准公司2024财年高管薪酬方案 • 通过普通股授权增发议案，将法定流通股数量从2.5亿股提升至5亿股 • 修订2021年综合激励计划，新增500万股授权发行额度
本次股东大会通过的增发决议显著扩充了公司资本运作空间，而激励计划的调整将为核心人才保留提供更强力支持。市场分析人士指出，双重股权扩容举措可能为后续战略布局铺路，特别是在烟草减害与植物基合成生物学等核心业务领域。
（免责声明：本文基于美国证券交易委员会EDGAR系统披露文件创作，仅供参考不构成投资建议。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.